MedTech Regulatory Challenges & Solutions
Six problems that cost device and IVD manufacturers time, budget and market access, and the defined route we take through each one.
Global market access complexity
Each market classifies devices differently, expects different evidence and requires a different local legal role. Planning market by market wastes evidence and time.
- One regulatory roadmap covering every target market
- Evidence planned once and reused where the rules allow
- Local representation needs identified at the start
- Country pages and a regulatory navigator to frame the first conversation
Regulatory documentation burden
Technical documentation, clinical and performance evidence and remediation compete for the same small team, and quality slips when deadlines stack up.
- Gap assessments that rank findings by risk
- Controlled authoring and remediation of technical files, CERs and PERs
- Independent SME and QC review before anything is submitted
- WriteCortex AI, now in testing and validation, for structured, evidence-linked first drafts
Quality system transformation
QMSR now applies in the US, MDSAP is expected in several markets, and FDA inspection now reaches management review and internal audit records.
- QMSR readiness assessment with a prioritised remediation plan
- ISO 13485 implementation and multi-site harmonisation
- Mock audits and objective evidence preparation
- Outsourced or co-sourced QMS support
Clinical evidence gaps
Equivalence that no longer holds, outdated literature, PMCF without clear objectives, or IVD performance data that does not support the claims made.
- Clinical evidence gap assessment as a standalone engagement
- Reproducible literature methodology
- CER and PER authoring with medical review
- PMCF and PMPF designed around residual uncertainties
Post-market compliance
Complaints handled case by case, reportability decisions made under time pressure, and trends spotted only when the PSUR is due.
- Managed complaint handling unit
- Jurisdiction-by-jurisdiction reportability review
- Trend reporting that feeds CAPA and the risk file
- PMSR and PSUR authoring
AI and digital regulatory transformation
Teams want the speed of AI but cannot accept output that is untraceable or unreviewed in a regulated file.
- AI used for first-pass assessment, drafting and coding
- Specialist review of every output before it reaches the file
- Traceability from each finding or draft to its source
- A pilot on a controlled use case before wider adoption
Discuss your device, market or audit with a specialist
Share the device, its class and your target markets. A senior specialist will come back with the likely pathway, the evidence gaps we see and a practical plan.